Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | F2 | P00734 | 6/20 | 0.72 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6156677 | 0.99 | F10 (0.80) | F10KCNH2F2PRSS1 | |
| Hydrochloric Acid SCHEMBL8800574 | 0.93 | F10 (0.75) | F10KCNH2F2PRSS1 | |
| SCHEMBL7199874 | 0.92 | F10 (0.79) | F10KCNH2F2PRSS1 | |
| Hydrochloric Acid SCHEMBL6960473 | 0.91 | F10 (0.78) | F10KCNH2F2PRSS1 | |
| Hydrochloric Acid SCHEMBL6955566 | 0.91 | F10 (0.78) | F10KCNH2F2PRSS1 | |
| SCHEMBL7198338 | 0.90 | F10 (0.78) | F10KCNH2F2PRSS1 | |
| Hydrochloric Acid SCHEMBL6954719 | 0.89 | F10 (0.77) | F10KCNH2F2PRSS1 | |
| Hydrochloric Acid SCHEMBL8800542 | 0.89 | F10 (0.99) | F10KCNH2F2PRSS1 | |
| Hydrochloric Acid SCHEMBL6951907 | 0.89 | F10 (0.63) | F10KCNH2F2PRSS1 | |
| SCHEMBL8800030 | 0.88 | F10 (0.81) | F10KCNH2F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187249-A1 | An aqueous solution of a physiologically active substance which may have a substituent and which has an amidino group, the solution having a pH > 2 and -/< than 4; storage stability; parental injections; 2-[4-[((3S)-1-acetoimidoyl-3-pyrrolidinyl)oxy]phenyl] -3-(7-amidino-2-naphthyl)propionic acid; kits | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-08-25 | — | — | US | claimed |
| EP-1504755-A1 | LYOPHILIZATION PRODUCT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | claimed |
| EP-0798295-B1 | NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-02-26 | — | — | EP | claimed |
| EP-1043020-A1 | MEDICINAL COMPOSITION FOR PERCUTANEOUS ADMINISTRATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-11 | — | — | EP | claimed |
| EP-0966973-A1 | SORBEFACIENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-12-29 | — | — | EP | claimed |
| EP-0953359-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | claimed |
| EP-0798295-A1 | NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-10-01 | — | — | EP | claimed |
| US-20050187249-A1 | An aqueous solution of a physiologically active substance which may have a substituent and which has an amidino group, the solution having a pH > 2 and -/< than 4; storage stability; parental injections; 2-[4-[((3S)-1-acetoimidoyl-3-pyrrolidinyl)oxy]phenyl] -3-(7-amidino-2-naphthyl)propionic acid; kits | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1504755-A1 | LYOPHILIZATION PRODUCT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-6596754-B1 | Drug for hypercytokinemia, liver diseases, and syndromes caused by the aggravation of sepsis, containing an anti-thrombin agent and/or a thrombin production inhibitor as an active ingredient. The present invention is applicable to | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| EP-0798295-B1 | NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-02-26 | — | — | EP | disclosed |
| EP-1110556-A1 | PREVENTIVES/REMEDIES FOR MULTIPLE ORGAN FAILURE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-27 | — | — | EP | disclosed |
| EP-1043020-A1 | MEDICINAL COMPOSITION FOR PERCUTANEOUS ADMINISTRATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
| EP-0966973-A1 | SORBEFACIENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-12-29 | — | — | EP | disclosed |
| EP-0953359-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | disclosed |
| EP-0798295-A1 | NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187249-A1 | An aqueous solution of a physiologically active substance which may have a substituent and which has an amidino group, the solution having a pH > 2 and -/< than 4; storage stability; parental injections; 2-[4-[((3S)-1-acetoimidoyl-3-pyrrolidinyl)oxy]phenyl] -3-(7-amidino-2-naphthyl)propionic acid; kits | NGLY1, IDE, NPPA | F10 98/4885KCNH2 1792/4885F2 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.